Results 131 to 140 of about 72,428 (200)

Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer‐related death worldwide. Contemporary advances in systemic and locoregional therapies have led to changes in peer‐reviewed guidelines regarding systemic therapy as well as the possibility of downstaging disease that may enable some patients
Dimitrios Moris, Alessandro Martinino, Sarah Schiltz, Peter J. Allen, Andrew Barbas, Debra Sudan, Lindsay King, Carl Berg, Charles Kim, Mustafa Bashir, Manisha Palta, Michael A. Morse, Michael E. Lidsky   +12 more
wiley   +1 more source

Diffuse plane xanthomas as the first manifestation of multiple myeloma

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Eleni Koutra, Elke Lusmöller, Hosam Ghanem, Astrid Aumann, Jens Atzpodien, Rudolf Stadler   +5 more
wiley   +1 more source

Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a dismal prognosis, largely because of late‐stage diagnosis and therapeutic resistance. PDAC incidence has been rising, with modifiable and non‐modifiable risk factors contributing to disease development.
Alessandro Mannucci, Ajay Goel
wiley   +1 more source

Atezolizumab Plus Bevacizumab for TACE‐Unsuitable Intermediate‐Stage HCC Beyond Up‐To‐7 Criteria: Final Analysis of REPLACEMENT

Liver International, Volume 45, Issue 12, December 2025.
ABSTRACT Background and Aims The phase II REPLACEMENT study showed promising clinical benefit from atezolizumab plus bevacizumab in transcatheter arterial chemoembolization (TACE)–naïve patients with intermediate‐stage hepatocellular carcinoma (HCC) beyond up‐to‐7 criteria, meeting its primary endpoint of progression‐free survival (PFS).
Kazuomi Ueshima, Kaoru Tsuchiya, Tatsuya Yamashita, Shigeo Shimose, Kazushi Numata, Yuzo Kodama, Shinji Itoh, Yasuhito Tanaka, Hidekatsu Kuroda, Kazuyoshi Ohkawa, Teiji Kuzuya, Masafumi Ikeda, Youhei Kooka, Hiroshi Aikata, Atsushi Hiraoka, Michihisa Moriguchi, Ryosuke Tateishi, Sadahisa Ogasawara, Kouji Yamamoto, Masatoshi Kudo   +19 more
wiley   +1 more source

Rewriting the MASLD‐associated hepatocellular carcinoma script: Targeting epigenetics and metabolism

International Journal of Cancer, Volume 157, Issue 10, Page 1991-2003, 15 November 2025.
Abstract Abnormal epigenetic patterns are crucial for the progression of metabolic‐associated steatotic liver disease (MASLD) and hepatocellular carcinoma (HCC) development. Recent research focused on the interplay between epigenetics and altered metabolic pathways in HCC from MASLD, suggesting that the reversibility of epigenetic changes offers ...
Chiara Aiello, Eric Felli, Teresa Musarra, Lorenzo Nevi, Annamaria Altomare, Jordi Gracia‐Sancho, Andrea Baiocchini, Simone Carotti   +7 more
wiley   +1 more source

Artificial intelligence modelling of tyrosine kinase inhibitors at risk of malabsorption and bioavailability‐enhancing strategies

British Journal of Clinical Pharmacology, Volume 91, Issue 11, Page 3130-3140, November 2025.
Aims The study aims to predict and improve the absorption of tyrosine kinase inhibitors (TKIs) in patients with malabsorption issues, particularly those who have undergone bariatric surgery or are using proton‐pump inhibitors. The research involves 2 main components: the development of an artificial intelligence (AI) model to identify TKIs that are ...
Daan W. Huntjens, Olivier J. M. Béquignon, Stefanie D. Krens, Mark Löwenberg, Martine E. D. Chamuleau, Remco J. Molenaar, Anita M. G. Kramers, Marianne A. Kuijvenhoven, Imke H. Bartelink   +8 more
wiley   +1 more source

Hepatoid Adenocarcinoma of the Stomach Combined With Gastric Neuroendocrine Carcinoma: A Case Report

Clinical Case Reports, Volume 13, Issue 11, November 2025.
(a) Gastric resection (52‐year‐old man, initial presentation): poorly differentiated carcinoma, consistent with hepatoid adenocarcinoma with neuroendocrine differentiation. Carcinoma invaded the muscularis propria, and vascular tumor emboli were identified.
Banghui Ma, Ping Zheng, Yongdong Jin
wiley   +1 more source

A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens

Cancer, Volume 131, Issue 21, 1 November 2025.
ABSTRACT Advances in the prognostication, monitoring, and treatment of both the acute and chronic leukemias have led to drastically improved outcomes over the past 2 decades. With the advent of targeted therapies, including antibodies such as blinatumomab and inotuzumab and small molecule inhibitors, such as the BCR::ABL1 tyrosine kinase inhibitors ...
Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, Courtney DiNardo, Guillermo Garcia‐Manero, Ghayas Issa, Elias Jabbour, Nitin Jain, Tapan Kadia, Sanam Loghavi, Farhad Ravandi, Guilin Tang, Mary Alma Welch, William Wierda   +13 more
wiley   +1 more source

Cuproptosis‐Related Ferroptosis Gene Signature: A Prognostic Tool for Colon Cancer Patients

Cancer Reports, Volume 8, Issue 11, November 2025.
ABSTRACT Background Ferroptosis and cuprotosis, two distinct mechanisms of programmed cell death, play key roles in colon cancer development. This study aimed to construct a prognostic model for predicting colon adenocarcinoma (COAD) prognosis based on the differential expression of cuproptosis‐related ferroptosis genes (CFRGs).
Yanlin Tan, Jinxiu Zhang, Ruoxi Cheng, Wenfang Yang, Xiaoping Pan, Kaoyan Feng, Mengbin Qin, Jie'an Huang   +7 more
wiley   +1 more source

Cancer‐Associated Fibroblasts: Origin, Classification, Tumorigenicity, and Targeting for Cancer Therapy

MedComm, Volume 6, Issue 11, November 2025.
This review explores the multifaceted roles of cancer‐associated fibroblasts (CAFs) in tumor biology. It examines their diverse origins, dynamic activation via signaling pathways, and spatial–temporal heterogeneity, proposing an updated classification of eight distinct CAF subtypes. The review highlights CAFs' contributions to tumor growth, metastasis,
Chang Fan, Wenlong Zhu, Yuan Chen, Wanwan Zhu, Jin Ding   +4 more
wiley   +1 more source